Keyword Analysis & Research: nct02054806

Keyword Analysis



Keyword Research: People who searched nct02054806 also searched

Frequently Asked Questions

What is keynote-028 (nct02054806)?

Patients and Methods KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1–positive advanced solid tumors.

What is the NCT number for the pembrolizumab clinical trial?

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02054806 Alley EW, Lopez J, Santoro A, Morosky A, Saraf S, Piperdi B, van Brummelen E. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.

What is the keykeynote-028 trial?

KEYNOTE-028 (NCT02054806) is a nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1–positive advanced solid tumors.

Is pembrolizumab (MK-3475) effective in incurable advanced biomarker-positive solid tumors?

This study will assess the efficacy and safety of pembrolizumab (MK-3475) administered to participants with incurable advanced biomarker-positive solid tumors that have not responded to current therapy or for which current therapy is not appropriate.


Search Results related to nct02054806 on Search Engine